Genprex, Inc.

35 articles with Genprex, Inc.

• Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum

  5/21/2019

  Genprex, Inc., a clinical-stage gene therapy company, announced it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria Chicago on May 31, 2019.

• Genprex Retains Addison Whitney for Drug Nomenclature Branding

  5/8/2019

  Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it has taken a significant step toward commercialization of its lead drug candidate by retaining the services of leading pharmaceutical branding agency, Addison Whitney.

• Genprex Collaborators Report Positive TUSC2 and Checkpoint Blockade Preclinical Data at the 2019 AACR Annual Meeting

  4/8/2019

  TUSC2 Immunogene Therapy Overcomes Resistance to Checkpoint Blockade

• Genprex Provides Clinical, Corporate, and Financial Update for the Year Ending December 31, 2018

  4/1/2019

  Today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K with the United States Securities and Exchange Commission.

• Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City

  3/14/2019

  Alliance for Regenerative Medicines’ Seventh Annual Investors Conference

• Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors

  2/19/2019

  Experienced Biotech Executive Brings More Than 30 Years of Pharmaceutical and Biotechnology Experience to Genprex

• Genprex to Present at NobleConXV in Fort Lauderdale, Florida

  1/23/2019

  Noble Capital Markets' Fifteenth Annual Investor / Equity Conference

• Genprex to Present at Biotech Showcase™ 2019 in San Francisco

  1/3/2019

  Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare finance at the Hilton San Francisco Union Square.

• 

  A Look at the Year's Most and Least Successful Biotech IPOs

  1/3/2019

  Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.

• Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019

  12/12/2018

  Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it will be increasing its investor relations efforts in 2019, spearheaded by the launch of an innovative corporate website

• Genprex to Present at the 11th Annual LD Micro Main Event

  12/3/2018

  Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that its Chairman and Chief Executive Officer, Rodney Varner, will present at the 11th annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

• Genprex Provides Clinical and Corporate Update for Third Quarter 2018

  11/20/2018

  Filing of quarterly results for the third quarter ended September 30, 2018 on Form 10-Q with the Securities and Exchange Commission.

• Genprex Appoints Jan Stevens, RN, as Vice President of Clinical Operations

  10/30/2018

  Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Jan Stevens, RN, as the Company’s Vice President of Clinical Operations.

• Genprex to Present at Upcoming Investor and Industry Conferences

  10/1/2018

  Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer

• Genprex Amends Options to License Additional Cancer Fighting Technologies from the University of Texas MD Anderson Cancer Center

  8/28/2018

  Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered into amendments with The University of Texas MD Anderson Cancer Center (MD Anderson) to extend the terms of two option agreements between Genprex and MD Anderson

• Genprex Provides Clinical and Corporate Update for Second Quarter 2018

  8/15/2018

  Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform

• Genprex Updates Agreement with University of Texas MD Anderson Cancer Center to Resume Patient Enrollment in Phase I/II Study Evaluating Oncoprex/Erlotinib Combination Therapy in Non-Small Cell Lung Cancer

  8/2/2018

  Genprex, Inc. announced that it has amended its agreement with The University of Texas MD Anderson Cancer Center to resume patient enrollment in its Phase I/II clinical trial evaluating the combination of the company’s investigational drug Oncoprex™ and erlotinib (Tarceva®)

• Genprex Enters Agreement with the University of Texas MD Anderson Cancer Center to Study Oncoprex in Combination with Immunotherapies

  7/26/2018

  New study will evaluate synergistic effect of Oncoprex gene therapy on checkpoint inhibition

• Genprex To Present At The Singular Research Summer Solstice 2018 Conference

  7/18/2018

  Genprex, Inc. announced that Rodney Varner, Chairman and Chief Executive Officer, will present at the Singular Research Summer Solstice 2018 Conference to be held on July 19th in New York, New York.

• Diamond Equity Research Initiates Coverage on Genprex Inc. (NASDAQ: GNPX) with a Valuation of $13 Per Share

  7/2/2018

  Diamond Equity Research, a leading equity research and corporate access firm with a focus on small capitalization public companies has initiated coverage of Genprex Inc.